Patents by Inventor Qinghua Mao
Qinghua Mao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240105211Abstract: The present disclosure provides a weakly-supervised sound event detection method and system based on adaptive hierarchical pooling. The system includes an acoustic model and an adaptive hierarchical pooling algorithm module (AHPA-model), where the acoustic model inputs a pre-processed and feature-extracted audio signal, and predicts a frame-level prediction probability aggregated by the AHPA-module to obtain a sentence-level prediction probability. The acoustic model and a relaxation parameter are jointly optimized to obtain an optimal model weight and an optimal relaxation parameter based for formulating each category of sound event. A pre-processed and feature-extracted unknown audio signal is input to obtain frame-level prediction probabilities of all target sound events (TSEs), and sentence-level prediction probabilities of all categories of TSEs are obtained based on an optimal pooling strategy of each category of TSE.Type: ApplicationFiled: June 27, 2022Publication date: March 28, 2024Applicant: Jiangsu UniversityInventors: Qirong MAO, Lijian GAO, Yaxin SHEN, Qinghua REN, Yongzhao ZHAN, Keyang CHENG
-
Publication number: 20220324897Abstract: Crystal form A of a compound represented by formula (I) and an application thereof in preparing a drug for treating an SGLT1/SGLT2-related disease.Type: ApplicationFiled: July 3, 2020Publication date: October 13, 2022Inventors: Qinghua MAO, Tao YU, Yi LI, Chengde WU, Ting YAO
-
Publication number: 20220259247Abstract: A class of compounds as a SGLT1/SGLT2/DPP4 triple inhibitor, and an application in preparation of a drug serving as the SGLT1/SGLT2/DPP4 triple inhibitor. Compounds represented by formula (I), and isomers and pharmaceutically-acceptable salts thereof are specifically involved.Type: ApplicationFiled: July 24, 2020Publication date: August 18, 2022Applicant: DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL CO., LTD.Inventors: Qinghua MAO, Tao YU, Yi LI, Chengde WU, Shuhui CHEN
-
Publication number: 20220242898Abstract: Compounds as SGLT2/DPP4 dual inhibitors, and application in preparation of medicines as the SGLT2/DPP4 dual inhibitors. A compound represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof are specifically involved.Type: ApplicationFiled: July 24, 2020Publication date: August 4, 2022Inventors: Qinghua MAO, Tao YU, Lu GAN, Yi LI, Chengde WU, Shuhui CHEN
-
Publication number: 20220153772Abstract: A glucoside derivative that acts as an SGLT1 inhibitor and an application thereof in the preparation of a drug for SGLT1 related diseases. Specifically disclosed is a compound represented by formula (II), a tautomer thereof or a pharmaceutically acceptable composition thereof.Type: ApplicationFiled: March 30, 2020Publication date: May 19, 2022Applicant: MEDSHINE DISCOVERY INC.Inventors: Yi LI, Tao YU, Qinghua MAO, Chengde WU, Shuhui CHEN
-
Patent number: 11021486Abstract: Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.Type: GrantFiled: June 22, 2018Date of Patent: June 1, 2021Assignees: CSTONE PHARMACEUTICALS, CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD., CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD.Inventors: Qinghua Mao, Chengde Wu, Yong Huang, Zhen Gong, Jian Li, Shuhui Chen
-
Patent number: 10822365Abstract: A compound as an SGLT1/SGLT2 dual inhibitor, and an application thereof in the preparation of a drug as the SGLT1/SGLT2 dual inhibitor. The compound is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 30, 2020Date of Patent: November 3, 2020Inventors: Chengde Wu, Qinghua Mao, Yi Li, Tao Yu, Shuhui Chen
-
Publication number: 20200331950Abstract: A compound as an SGLT1/SGLT2 dual inhibitor, and an application thereof in the preparation of a drug as the SGLT1/SGLT2 dual inhibitor. The compound is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 30, 2020Publication date: October 22, 2020Inventors: CHENGDE WU, QINGHUA MAO, YI LI, TAO YU, SHUHUI CHEN
-
Publication number: 20200148695Abstract: Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.Type: ApplicationFiled: June 22, 2018Publication date: May 14, 2020Applicants: CSTONE PHARMACEUTICALS, CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD., CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD.Inventors: Qinghua MAO, Chengde WU, Yong HUANG, Zhen GONG, Jian LI, Shuhui CHEN
-
Patent number: 9914736Abstract: The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.Type: GrantFiled: March 23, 2015Date of Patent: March 13, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Ping Liu, Dann Parker, Chun Sing Li, Qinghua Mao
-
Patent number: 9896447Abstract: The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.Type: GrantFiled: September 17, 2014Date of Patent: February 20, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Chun Sing Li, Qinghua Mao
-
Patent number: 9862716Abstract: The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.Type: GrantFiled: March 23, 2015Date of Patent: January 9, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Yi-Heng Chen, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Swati P. Mercer, Keith P. Moore, Ping Liu, Harold B. Wood, Chun Sing Li, Qinghua Mao, Douglas C. Beshore
-
Patent number: 9862707Abstract: The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.Type: GrantFiled: March 23, 2015Date of Patent: January 9, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Helen Mitchell, Harold B. Wood, Chun Sing Li, Qinghua Mao, Zhiqi Qi
-
Patent number: 9815846Abstract: The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.Type: GrantFiled: March 23, 2015Date of Patent: November 14, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Yi-Heng Chen, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Swati P. Mercer, Kerim Babaoglu, Dongfang Meng, Jane Wu, Ping Liu, Harold B. Wood, Jianming Bao, Chun Sing Li, Qinghua Mao, Zhiqi Qi
-
Patent number: 9718782Abstract: The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.Type: GrantFiled: September 17, 2014Date of Patent: August 1, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Chun Sing Li, Qinghua Mao
-
Publication number: 20170158698Abstract: The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.Type: ApplicationFiled: March 23, 2015Publication date: June 8, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Ping Liu, Dann Parker, Chun Sing Li, Qinghua Mao
-
Publication number: 20170114071Abstract: The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.Type: ApplicationFiled: March 23, 2015Publication date: April 27, 2017Applicants: Merck Sharp & Dohme Corp., MSD R & D (China) Co., LTD.Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Yi- Heng Chen, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Swati P. Mercer, Kerim Babaoglu, Dongfang Meng, Jane Wu, Ping Liu, Harold B. Wood, Jianming Bao, Chun Sing Li, Qinghua Mao, Zhiqi Qi
-
Publication number: 20170114056Abstract: The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.Type: ApplicationFiled: March 23, 2015Publication date: April 27, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Yi- Heng Chen, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Swati P. Mercer, Keith P. Moore, Ping Liu, Harold B. Wood, Chun Sing Li, Qinghua Mao, Douglas C. Beshore
-
Publication number: 20170107204Abstract: The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.Type: ApplicationFiled: March 23, 2015Publication date: April 20, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Helen Mitchell, Harold B. Wood, Chun Sing Li, Qinghua Mao, Zhiqi Qi
-
Publication number: 20160229850Abstract: The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.Type: ApplicationFiled: September 17, 2014Publication date: August 11, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Chun Sing Li, Qinghua Mao